OKYO Pharma Ltd ADR Cash Flow Conversion Efficiency
OKYO Pharma Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has a cash flow conversion efficiency ratio of -0.357x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.41 Million) by net assets ($12.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OKYO Pharma Ltd ADR (2008–2026)
Cash flow conversion efficiency of OKYO Pharma Ltd ADR from 2008 to 2026. This chart illustrates how OKYO Pharma Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest OKYO Pharma Ltd ADR stock price today for real-time trading data and today's change.
OKYO Pharma Ltd ADR Cash Flow Conversion Ratio Explained
OKYO Pharma Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OKYO Pharma Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OKYO Pharma Ltd ADR ranked by their cash flow conversion efficiency. Also see OKYO Pharma Ltd ADR market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HLB Global Co Ltd
KO:003580
|
-0.045x |
|
Copenhagen Capital A/S
CO:CPHCAP-ST
|
0.015x |
|
Cactus Acquisition Corp 1 Ltd
NASDAQ:CCTS
|
-0.033x |
|
Tomei Consolidated Bhd
KLSE:7230
|
-0.004x |
|
Skane mollan AB
ST:SKMO
|
0.022x |
|
iNtRON Biotechnology Inc
KQ:048530
|
-0.013x |
|
Snowman Logistics Limited
NSE:SNOWMAN
|
0.109x |
|
Daesung Hi-Tech Co. Ltd.
KQ:129920
|
-0.050x |
Annual Cash Flow Conversion Efficiency for OKYO Pharma Ltd ADR (2008–2026)
The table below shows the annual cash flow conversion efficiency of OKYO Pharma Ltd ADR from 2008 to 2026. Review OKYO Pharma Ltd ADR financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $12.34 Million | $-5.94 Million | -0.481x | -247.47% |
| 2025-03-31 | $-5.55 Million | $-1.81 Million | 0.326x | -79.78% |
| 2024-03-31 | $-5.88 Million | $-9.49 Million | 1.614x | -56.93% |
| 2023-03-31 | $-2.05 Million | $-7.70 Million | 3.748x | +302.02% |
| 2022-03-31 | $2.95 Million | $-5.47 Million | -1.855x | -516.71% |
| 2021-03-31 | $5.32 Million | $-1.60 Million | -0.301x | -103.50% |
| 2020-03-31 | $-139.80K | $-1.20 Million | 8.599x | +243.95% |
| 2019-03-31 | $333.14K | $-1.99 Million | -5.973x | -617.91% |
| 2018-03-31 | $1.92 Million | $-1.59 Million | -0.832x | -3413.06% |
| 2017-03-31 | $27.50 Million | $-651.27K | -0.024x | -16.45% |
| 2016-03-31 | $32.00 Million | $-650.88K | -0.020x | +51.37% |
| 2015-03-31 | $33.90 Million | $-1.42 Million | -0.042x | +43.12% |
| 2014-03-31 | $46.96 Million | $-3.45 Million | -0.074x | +13.40% |
| 2013-03-31 | $45.02 Million | $-3.82 Million | -0.085x | +24.82% |
| 2012-03-31 | $41.36 Million | $-4.67 Million | -0.113x | -38.07% |
| 2011-03-31 | $16.01 Million | $-1.31 Million | -0.082x | -403.21% |
| 2010-03-31 | $54.05 Million | $-878.61K | -0.016x | -174.19% |
| 2009-03-31 | $38.18 Million | $-226.35K | -0.006x | +68.33% |
| 2008-03-31 | $27.46 Million | $-513.95K | -0.019x | -- |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more